Taysha Gene Therapies
Update in progressTSHA (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Taysha Gene Therapies is a clinical-stage biotech developing adeno-associated virus–based gene therapies for severe monogenic CNS diseases. Its programs include TSHA-120 (giant axonal neuropathy), TSHA-102 (Rett syndrome), TSHA-121 (CLN7), TSHA-118 (CLN1), TSHA-105 (SLC13A5 deficiency), TSHA-113 (tauopathies), TSHA-106 (Angelman), and TSHA-114 (fragile X). It collaborates with UT Southwestern. Founded in 2019, based in Dallas, TX.
Company score
- Sentiment
- 0.36
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.28
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Sean P. Nolan
- Founded2019
- Employees99
- Websitewww.tayshagtx.com
Identifiers
- ISINUS8776191061
- FIGIBBG00TJXFDP1
- CUSIP877619106
- CIK0001806310